Treatment with recombinant Anx-A1 has been shown to reduce cytomegalovirus infection by an unknown mechanism in human foreskin fibroblasts [19], suggesting the potential of cell surface Anx-A1 to mediate virus binding. This evidence concerns the gene ANXA1 and cytomegalovirus infection.